# OnCo record hld-0915 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/hld-0915/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "hld-0915" ;
  schema:name "HLD-0915 (JNJ-101556143)"@en ;
  schema:alternateName "HLD-0915"@en, "JNJ-101556143"@en ;
  schema:description "HLD-0915 (JNJ-101556143) is an experimental oral heterobifunctional small molecule from Halda Therapeutics, in phase 1 trials for metastatic prostate cancer."@en ;
  schema:url <https://onco.cc/drugs/hld-0915/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://medicaldialogues.in/amp/news/industry/pharma/jnj-completes-acquisition-of-halda-therapeutics-its-novel-platform-for-cancer-treatment-161646>, <https://www.indianpharmapost.com/news/johnson-johnson-completes-305-billion-acquisition-of-halda-therapeutics-18745>, <https://clinicaltrials.gov/study/NCT06095089>, <https://clinicaltrials.gov/search?intr=HLD-0915> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral heterobifunctional small molecule (RIPTAC)" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:companies <https://onco.cc/companies/halda-therapeutics/>, <https://onco.cc/companies/johnson-johnson/> ;
  onco:trials <https://onco.cc/trials/nct06800313/>, <https://onco.cc/trials/nct06095089/> .